I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 595537351 US, in an envelope addressed to: MS PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: March 23, 2006

Signature: (Georgica Matos)

Patent Docket No. 254082000700 Client Reference No. 16959/US/03

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Abdullah I. HAJ-YEHIA et al.

Application No.: 10/536,628

Int'l Application No.: PCT/IL2003/001006

International Filing Date: November 27, 2003

For: ACE-INHIBITORS HAVING

ANTIOXIDANT AND NITRIC OXIDE-

**DONOR ACTIVITY** 

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS PCT Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

	This Information Disclosure Statement is submitted:
	With the application; accordingly, no fee or separate requirements are required.
	Before the mailing of a first Office Action after the filing of a Request for Continued
	Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97
	(e)(1) has been provided.
$\boxtimes$	Within three months of the application filing date or before mailing of a first Office Action
	on the merits; accordingly, no fee or separate requirements are required. However, if
	applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
	After receipt of a first Office Action on the merits but before mailing of a final Office Action
	or Notice of Allowance.
	A fee is required. A check in the amount of is enclosed.
	A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to
	this submission in duplicate.
	A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is
	believed to be due.
	After mailing of a final Office Action or Notice of Allowance, but before payment of the
	issue fee.
	A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the
	amount of is enclosed.
	A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal
	form (PTO/SB/17) is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist;

(iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 254082000700.

Dated: March 22, 2006

Respectfully submitted,

Kimberly A. Bolin

Registration No.: 44,546

MORRISON & FOERSTER LLP

755 Page Mill Road

Palo Alto, California 94304-1018

(650) 813-5740

3

pa-1053184

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 1

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 2

Complete it Known		
Application Number	10/563628	
Filing Date	(Intl.) November 27, 2003	
First Named Inventor	HAJ-YEHIA, Abdullah	
Art Unit	Not Yet Assigned	
Examiner Name	Not Yet Assigned	
Attorney Docket Number	254082000700	

			U. S. PATEN	DOCUMENTS		
Examiner Initials*			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	AA	<sup>US-</sup> 5,025,001	03-24-1989	LOSCALZO, Joseph et al.		
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
-		US-				
-		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
	<b>†</b>	US-				

Examiner Initials*	Cite No.1		Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3 -</sup> Number <sup>4 -</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	™
	ВА	WO 98/21193	05-22-1998	DEL SOLDATO, Piero et al.		
	BB	WO 98/42661	10-01-1998	HAJ-YEHIA, Abdullah	٥	
	вс	WO 99/37616	07-29-1999	HAJ-YEHIA, Abdullah		
	BD	WO 00/61541	10-25-2001	DEL SOLDATO, Piero		
	BE	WO 02/34303	05-02-2002	LOSCALZO, Joseph et al.		

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
of a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO	Complete if Known		
	Application Number	10/563628	
INFORMATION DISCLOSURE	Filing Date	(Intl.) November 27, 2003	
STATEMENT BY APPLICANT	First Named Inventor	HAJ-YEHIA, Abdullah	
(Use as many sheets as necessary)	Art Unit	Not Yet Assigned	
(ose as many sheets as necessary)	Examiner Name	Not Yet Assigned	
Sheet 2 of 2	Attorney Docket Number	254082000700	

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*				
	CA	ARUOMA O. I. et al., "Evaluation of the ability of the angiotesin-converting enzyme inhibitor captopril to scavenge reactive oxygen species", CHEMICO-BIOLOGICAL INTERACTIONS, V		
	СВ	DJORDJEVIC V. B. et al., "Changes of lipid peroxides and antioxidative factors levels in blood of patients treated with ace inhibitors", CLINICAL NEPHROLOGY, DUSTRI VERLAG, NU		
	СС	IWANAGA Y. et al., "A nitric oxide-releasing derivative of enalapril NCX 899, prevents progressive LV dysfunction and improves remodeling in cardiomyopathic hamsters with hear		
	CD	JIA LEE et al., "The effects of S-nitrosocaptropril on renal filtration blood pressure in rats", EUROPEAN JOURNAL OF PHARMACOLOGY, Vol 354 no. 1 (1998) pp. 33-41;XP02277634		
	CE	VAN DER GIET M. et al., "Captopril and quinapril reduce reactive oxygen species" EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, Vol. 32 no. 10 (2002) pp.732-737;XP002277635		
-				

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.